Ono Venture Investment (OVI) is the corporate venture capital arm of ONO Pharmaceutical, a Japanese company founded in 1717. Established in 2020 in San Francisco, OVI manages a $200M evergreen fund, investing in global pre-clinical startups with unique platforms in human therapeutics. The firm typically invests up to $5M in Seed and Series A rounds, with a total of up to $10M per company. OVI has invested in 14 companies, mainly in Europe and the US.